Response to Treatment and Survival of Patients with Non-Small Cell Lung Cancer Undergoing Somatic EGFR Mutation Testing-Reference-Cited by-同舟云学术

Response to Treatment and Survival of Patients with Non-Small Cell Lung Cancer Undergoing Somatic EGFR Mutation Testing

Published:2007-01-01 Issue:1 Volume:12 Page:90-98
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Sequist Lecia V.¹,Joshi Victoria A.¹,Jänne Pasi A.¹,Muzikansky Alona¹,Fidias Panos¹,Meyerson Matthew¹,Haber Daniel A.¹,Kucherlapati Raju¹,Johnson Bruce E.¹,Lynch Thomas J.¹

Affiliation:

1. Massachusetts General Hospital Cancer Center, Harvard Medical School/Partners HealthCare Center for Genetics and Genomics, Massachusetts General Hospital Department of Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts,USA

Abstract

Learning Objectives After completing this course, the reader will be able to: Identify clinical factors that predict for the presence of a somatic EGFR mutation.Discuss clinical outcomes that may differ depending on EGFR mutation status.Describe the more common types of EGFR mutations that have defined clinical implications, as compared to the rare EGFR mutations of which the significance is not yet known. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com

Funder

National Service Research

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.12-1-90

Reference44 articles.

1. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results;Breathnach;J Clin Oncol,2001

2. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;Schiller;N Engl J Med,2002

3. Targeted therapy for the treatment of advanced non-small cell lung cancer: A review of the epidermal growth factor receptor antagonists;Silvestri;Chest Dec,2005